WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo

WAKAMOTO PHARMACEUTICAL CO.,LTD.

Develops gastrointestinal and ophthalmic drugs for the health challenges of an aging society.

4512 | T

Overview

Corporate Details

ISIN(s):
JP3991200001
LEI:
Country:
Japan
Address:
中央区日本橋本町二丁目2番2号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Wakamoto Pharmaceutical Co., Ltd. is a research-driven pharmaceutical company engaged in the development, manufacturing, and sale of prescription (ethical) and over-the-counter (OTC) medicines. The company specializes in two primary therapeutic areas: gastroenterology and ophthalmology. Its product portfolio includes the well-known gastrointestinal drug "Strong Wakamoto," which utilizes a proprietary microorganism to produce digestive enzymes, and a range of ophthalmic solutions for treating eye disorders. Wakamoto Pharmaceutical focuses its research and development efforts on creating medications and medical equipment to address the health challenges of an aging society.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 08:03
Registration Form
確認書
Japanese 8.1 KB
2025-11-13 08:03
Interim Report
半期報告書-第131期(2025/04/01-2026/03/31)
Japanese 182.0 KB
2025-06-27 10:03
Post-Annual General Meeting Information
臨時報告書
Japanese 24.7 KB
2025-06-20 08:53
Governance Information
内部統制報告書-第130期(2024/04/01-2025/03/31)
Japanese 21.5 KB
2025-06-20 08:51
Registration Form
確認書
Japanese 8.1 KB
2025-06-20 08:48
Annual Report
有価証券報告書-第130期(2024/04/01-2025/03/31)
Japanese 1014.1 KB
2025-02-06 08:28
Major Shareholding Notification
臨時報告書
Japanese 19.3 KB
2024-11-13 01:51
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-11-13 01:46
Interim Report
半期報告書-第130期(2024/04/01-2025/03/31)
Japanese 183.5 KB
2024-07-02 05:00
Post-Annual General Meeting Information
臨時報告書
Japanese 33.6 KB
2024-06-28 08:24
Governance Information
内部統制報告書-第129期(2023/04/01-2024/03/31)
Japanese 21.7 KB
2024-06-28 08:21
Registration Form
確認書
Japanese 8.1 KB
2024-06-28 08:19
Annual Report
有価証券報告書-第129期(2023/04/01-2024/03/31)
Japanese 1007.9 KB
2024-02-14 01:17
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-02-14 01:17
Quarterly Report
四半期報告書-第129期第3四半期(2023/10/01-2023/12/31)
Japanese 155.8 KB

Automate Your Workflow. Get a real-time feed of all WAKAMOTO PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for WAKAMOTO PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for WAKAMOTO PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Idorsia Ltd Logo
Develops and commercializes small-molecule medicines for CNS, cardiovascular, and immune disorders.
Switzerland
IDIA
IGC Pharma, Inc. Logo
Clinical-stage pharma creating Alzheimer's therapies & AI-powered diagnostics.
United States of America
IGC
IL DONG PHARMACEUTICAL CO., LTD. Logo
Develops & manufactures pharmaceuticals, APIs, and offers CMO services for various diseases.
South Korea
249420
ILSUNG IS CO., LTD. Logo
Develops pharmaceuticals like antibiotics and anesthetics, expanding into CNS and GI therapies.
South Korea
003120
ILYANG PHARMACEUTICAL CO.,LTD Logo
Develops & manufactures drugs, vaccines & supplements for oncology & gastroenterology needs.
South Korea
007570
I-Mab Logo
A clinical-stage biopharma developing immuno-oncology agents and bispecific antibodies for cancer.
United States of America
IMAB
ImageneBio, Inc. Logo
A clinical-stage biopharma pioneering therapies for immune & inflammatory diseases.
United States of America
IMA
IM Cannabis Corp. Logo
International producer of medical-grade cannabis for patients and providers in Israel and Germany.
United States of America
IMCC
Immatics N.V. Logo
Develops T-cell redirecting immunotherapies (ACT & TCR Bispecifics) for solid tumor cancers.
United States of America
IMTX
Immix Biopharma, Inc. Logo
Developing safer cell therapies for AL Amyloidosis and hematologic malignancies.
United States of America
IMMX

Talk to a Data Expert

Have a question? We'll get back to you promptly.